Screener
Syndax Pharmaceuticals SNDX Business Segments — Personnel Cost And Other General Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:PersonnelCostAndOtherGeneralExpenses.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Personnel cost and other expenses | 19,298 | 16,531 |
| General and administrative expenses | ||
| Commercial related expenses | 7,721 | 10,825 |
| Personnel cost and other expenses | 16,701 | 19,082 |
| Other SG&A expenses | 5,140 | 4,412 |
| Stock-based compensation | 12,053 | 10,380 |
| Royalty interest expense | 11,846 | 8,049 |
| Interest expense (income), net | (3,561) | (7,181) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — personnel cost and other general expenses?
- Syndax Pharmaceuticals (SNDX) reported business segments — personnel cost and other general expenses of $16.7M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — personnel cost and other general expenses changed year-over-year?
- Syndax Pharmaceuticals's business segments — personnel cost and other general expenses decreased by 12.5% year-over-year, from $19.08M to $16.7M.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — personnel cost and other general expenses?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — personnel cost and other general expenses has grown at a 84.8% compound annual growth rate (CAGR), from $11.3M to $71.27M.
- What does business segments — personnel cost and other general expenses mean?
- This captures the administrative and general support costs associated with the personnel managing the cancer therapeutics business unit. It covers overhead functions that support the segment's operations beyond direct R&D or sales activities. Tracking this helps investors understand the operational leverage and administrative burden of the business segment.
Ask your AI about Syndax Pharmaceuticals's business segments — personnel cost and other general expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude